

Serial No. 10/529,873  
Atty. Docket No.: P68228US1

**Listing of Claims:**

1. (Original) Construct for transdermal delivery of at least one immunogen to an individual comprising:

- a) said at least one immunogen;
- b) an occlusion vehicle and
- c) an immunogen delivery system

wherein the immunogen delivery system is a complex comprising:

- i) at least one first sterol and/or at least one second sterol,

wherein the at least one second sterol is capable of contacting a genetic determinant by means of an interaction selected from an electrostatic interaction and a hydrophobic interaction, and wherein the at least one first sterol and/or the at least one second sterol is capable of forming a complex with at least one first saponin and/or at least one second saponin, and

- ii) at least one first saponin and/or at least one second saponin,

wherein the at least one second saponin is capable of contacting a genetic determinant by means of an interaction selected from an electrostatic interaction and a hydrophobic interaction, and wherein the at least one first saponin and/or the at least one second saponin is capable of forming a complex with at least one

Serial No. 10/529,873  
Atty. Docket No.: P68228US1

first sterol and/or at least one second sterol, and optionally

iii) at least one contacting group for contacting a genetic determinant by means of an interaction selected from an electrostatic interaction and a hydrophobic interaction,

with the proviso that the at least one contacting group is present when no second sterol is present in the complex and further optionally

iv) at least one lipophilic moiety.

2. (Original) Construct according to claim 1, wherein the occlusion vehicle is a pressure sensitive adhesive.

3. (Cancelled)

4. (Previously presented) Construct according to claim 1, wherein the transdermal delivery includes delivery through a skin surface or through a mucous membrane tissue.

5. (Previously presented) Construct according to claim 1, wherein the occlusion vehicle is a absorbing pressure sensitive adhesive.

Serial No. 10/529,873  
Atty. Docket No.: P68228US1

6. (Previously presented) Construct according to claim 1, wherein the occlusion vehicle is a hydrocolloid adhesive.

7. (Previously presented) Construct according to claim 1, wherein the occlusion vehicle is a hydrogel adhesive.

8. (Previously presented) Construct according to claim 1, wherein the occlusion vehicle is a cross-linked hydrogel adhesive.

9. (Previously presented) Construct according to claim 1, wherein the immunogen and the immunogen delivery system is distributed preferably homogenously in the occlusion vehicle.

10. (Previously presented) Construct according to claim 1, wherein the immunogen and the immunogen delivery system is distributed on the surface of the occlusion vehicle.

11. (Withdrawn) Construct according to claim 1, wherein the occlusion vehicle is a non-adherent occlusion vehicle, and further comprising a secondary adhesive, being separated from the vehicle, for skin fixation.

12. (Withdrawn) Construct according to claim 11, wherein the occlusion vehicle is dried or lyophilised and contains a carrier

Serial No. 10/529,873  
Atty. Docket No.: P68228US1

comprising a hydrophilic polymer substance or a grease like composition.

13. (Previously presented) Construct according to claim 1, wherein the occlusion vehicle or the secondary adhesive is a covering, such as a pad, a patch, a dressing or the like.

14. (Withdrawn) Construct according to claim 12 further comprising a reservoir of water or other appropriate solvent/diluent.

15. (Withdrawn) Construct according to claim 14, wherein the water reservoir can be broken and the water or solvent/diluent can be absorbed in the occlusion vehicle.

16. (Previously presented) Construct according to claim 1 further comprising a rate controlling membrane.

17. (Previously presented) Construct according to claim 1, wherein the immunogen and/or the immunogen delivery system is separated from each other.

18. (Previously presented) Construct according to claim 1 further comprising an enhancer for transdermal drug delivery.

Serial No. 10/529,873  
Atty. Docket No.: P68228US1

19. (Previously presented) Construct according to claim 1, wherein the at least one immunogen is selected in such a way that the induced immunological response is directed against one or more antigens.

20. (Original) Construct according to claim 19, wherein said one or more antigens are derived from a microorganism, preferably a pathogenic microorganism, such as a virus, a bacteria, a parasite and/or a fungus, or from a non-microbial organism, e.g. from an animal, such as a vertebrate.

21. (Previously presented) Construct according to claim 19, wherein the immunogen and/or antigen are derived from a virus.

22. (Original) Construct according to claim 21, wherein said one or more antigens are synthetic antigens, antigens derived from said individual or antigens derived from any species.

23. (Previously presented) Construct according to claim 19, wherein the at least one immunogen is selected in such a way that the induced immunological response confers protection in said individual against a pathogenic microorganism which said antigen or antigens are part of.

Serial No. 10/529,873  
Atty. Docket No.: P68228US1

24. (Previously presented) Construct according to claim 19, wherein the at least one immunogen is selected in such a way that the induced immunological response may act upon subsequent exposure of the individual to said pathogenic microorganism.

25. (Previously presented) Construct according to claim 19, wherein the at least one immunogen is selected in such a way that the induced immunological response is directed against a pathogenic component produced by said pathogenic microorganism during infection of said individual, e.g. bacterial toxins, such as tetanus toxin.

26. (Previously presented) Construct according to claim 1, wherein the immunogen and/or antigen comprise or consist of

- i) one or more identical or different polypeptides and/or peptides, which polypeptides and/or peptides optionally comprise posttranslational modifications,

- ii) one or more identical or different lipopeptides, such as polypeptides and/or peptides chemically linked to a lipid group,

- iii) one or more identical or different nucleic acid sequence or sequences, which may encode polypeptides and/or peptides, or

- iv) one or more identical or different polysaccharides

Serial No. 10/529,873  
Atty. Docket No.: P68228US1

and/or oligosaccharides,

or combinations thereof, and wherein the immunogen and/or antigen may further be processed into fragments.

27. (Previously presented) Construct according to claim 1, wherein the immunogen and the immunogen delivery system is comprised within a vaccine formulation.

28. (Cancelled).

29. (Withdrawn) Process for the preparation of a construct according to claim 1, comprising the steps of introducing the immunogen and the immunogen delivery system, which are optionally comprised within a vaccine formulation, into the matrix of the occlusion vehicle or on its surface by dispersion or soaking in a solution of the vehicle or by applying to its surface, and optionally sterilising and/or drying and/or seal packaging the construct.

30. (Withdrawn) Process according to claim 29 further comprising the step of drying or lyophilisation or the immunogen and the immunogen delivery system before introducing into the vehicle.

31. (Withdrawn) Process according to claim 29 further comprising

Serial No. 10/529,873  
Atty. Docket No.: P68228US1

the step of adding one or more enhancers for transdermal drug delivery and/or one or more plasticizers.

32. (Previously presented) Construct according to claim 1, having one or more compartments.

33. (Original) Construct according to claim 32 having at least two compartments, wherein a first compartment comprises a lyophilised pad comprising the immunogen and the immunogen delivery system and a second compartment comprises water or other appropriate solvent/diluent.

34. (Previously presented) Construct according to claim 1 comprising at least two separate components.

35. (Withdrawn) Method for generating an immunological response in an individual wherein said individual is treated transdermal with a construct according to claim 1.

36. (Withdrawn) Method for treating or preventing a condition of illness in an individual, e.g. a disease caused by infection of said individual by a pathogenic microorganism, wherein said individual is treated transdermal with a construct according to claim 1.



Serial No. 10/529,873  
Atty. Docket No.: P68228US1

37. (Withdrawn) Method for vaccination of an individual wherein said individual is treated transdermal with a construct according to claim 1.